Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012247 | 0.86 | TDO2 (0.44) | SYKGRM1BRAFMAPK1EGFR | |
| SCHEMBL16012244 | 0.80 | CCNT1 (0.43) | SYKEGFRBCL6KMT2AMEN1 | |
| SCHEMBL15146279 | 0.80 | AURKA (0.47) | SYKEGFRBCL6KMT2AMEN1 | |
| SCHEMBL16012714 | 0.79 | PIN1 (0.62) | SYKMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6507541 | 0.76 | ADORA3 (0.46) | EGFRBCL6KMT2AMEN1PIN1 | |
| SCHEMBL656737 | 0.74 | SYK (0.55) | SYKBCL6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL16012862 | 0.74 | MEN1 (0.48) | MAPK1PIK3CAEGFRBCL6KMT2A | |
| SCHEMBL2411693 | 0.74 | AURKA (0.53) | SYKEGFRBCL6KMT2AMEN1 | |
| SCHEMBL16264851 | 0.74 | MEN1 (0.45) | MAPK1EGFRBCL6KMT2AMEN1 | |
| SCHEMBL24654519 | 0.73 | PIN1 (0.57) | SYKMAPK1EGFRBCL6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | EIF2AK4, GCN1, EIF4A2 | SYK 4395/4885GRM1 546/4885BRAF 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.